• 1
    Neoptolemos JP, Stocken DD, Dunn JA et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann. Surg. 2001; 234: 75868.
  • 2
    Okamoto A, Tsuruta K, Karasawa K et al. Resection versus palliation: treatment of stage III and IVA carcinomas of the pancreas employing intraoperative radiation. World J. Surg. 2003; 27: 599605.
  • 3
    Baulieux J, Delpero JR. Surgical treatment of pancreatic cancer: curative resections. Ann. Chir. 2000; 125: 60917.
  • 4
    Beger HG, Gansauge F, Leder G. Pancreatic cancer: who benefits from curative resection? Can. J. Gastroenterol. 2002; 16: 11720.
  • 5
    Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J. Hepatobiliary Pancreat. Surg. 2004; 11: 410.
  • 6
    Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J. Gastroenterol. Hepatol. 2008; 23: 2333.
  • 7
    Vogt DP. Pancreatic cancer: a current overview. Curr. Surg. 2000; 57: 21420.
  • 8
    Magee CJ, Ghanch P, Neoptolemos JP. Surgical and medical therapy for pancreatic carcinoma. Best Pract. Res. Clin. Gastroenterol. 2002; 16: 43555.
  • 9
    Cappelli G, Paladini S, D'Agata A. Tumor markers in the diagnosis of pancreatic cancer. Tumori 1999; 85 (1 Suppl 1): S1921.
  • 10
    Civardi G, Cerri L, Cavanna L, Fornari F, Di Stasi M, Binelli F. Diagnostic accuracy of a new tumor serologic marker, CA 19-9: comparison with CEA. Tumori 1986; 72: 6214.
  • 11
    Del Favero G, Fabris C, Plebani M et al. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986; 57: 15769.
  • 12
    Frebourg T, Bercoff E, Manchon N et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 228790.
  • 13
    Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br. J. Cancer 1994; 69: 51519.
  • 14
    Safi F, Schlosser W, Falkenreck S, Beger HG. CA 19-9 serum course and prognosis of pancreatic cancer. Int. J. Pancreatol. 1996; 20: 15561.
  • 15
    Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 2003; 138: 9515.
  • 16
    Greene FL, Page DL, Flemming ID et al. Pancreatic adenocarcinoma. In: The American Joint Committee on Cancer Staging Handbook, 6th edn. New York: Springer, 2002.
  • 17
    Elferink RP. Understanding and controlling hepatobiliary function. Best Pract. Res. Clin. Gastroenterol. 2002; 16: 102534.
  • 18
    Raymond E, Boige V, Faivre S et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J. Clin. Oncol. 2002; 20: 430312.
  • 19
    Haller DG. New perspectives in the management of pancreas cancer. Semin. Oncol. 2003; 30 (4 Suppl. 11): 310.
  • 20
    Ellsmere J, Mortele K, Sahani D et al. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma? Surg. Endosc. 2005; 19: 36973.
  • 21
    Gulliver DJ, Baker ME, Cheng CA et al. Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. Am. J. Roentgenol. 1992; 159: 5037.
  • 22
    Prokesch RW, Chow LC, Beaulieu CF et al. Isoattenuating pancreatic adenocarcinoma at multi detector row CT: secondary signs. Radiology 2002; 224: 7648.
  • 23
    Saldinger PF, Reilly M, Reynolds K et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J. Gastrointest. Surg. 2000; 4: 2337.
  • 24
    Spitz FR, Abbruzzese JL, Lee JE et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin. Oncol. 1997; 15: 92837.
  • 25
    Steinberg WM, Barkin J, Bradley EL, 3rd et al. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998; 17: 2430.
  • 26
    Diehl SJ, Lehmann KJ, Sadick M et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998; 206: 3738.
  • 27
    Friess H, Kleeff J, Silva JC et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J. Am. Coll. Surg. 1998; 186: 67582.
  • 28
    Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J. Gastrointest. Surg. 1997; 1: 23643.
  • 29
    Rumstadt B, Schwab M, Schuster K et al. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J. Gastrointest. Surg. 1997; 1: 24550.
  • 30
    Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin. Gastroenterol. Hepatol. 2008; 12: 13018.
  • 31
    Kiliç M, Göçmen E, Tez M, Ertan T, Keskek M, Koç M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can. J. Surg. 2006; 49: 2414.
  • 32
    Fujioka S, Misawa T, Okamoto T et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J. Hepatobiliary Pancreat. Surg. 2007; 14: 53944.
  • 33
    Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J. Gastroenterol. 2008; 14: 37503.
  • 34
    Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983; 43: 548992.
  • 35
    Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45: 2539.
  • 36
    Mann DV, Edwards R, Ho S et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur. J. Surg. Oncol. 2000; 26: 4749.
  • 37
    Cerwenka H, Aigner R, Quehenberger F et al. Preoperative differential diagnosis of benign and malignant pancreatic lesions–the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B. CA19-9 and CEA. Hepatogastroenterology 1997; 44: 111721.
  • 38
    Ritts RE, Pitt HA. CA19-9 in pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998; 7: 93101.
  • 39
    Mery CM, Duarte-Rojo A, Paz-Pineda F, Gomez E, Robles-Diaz G. Does cholestasis change the clinical usefulness of CA19-9 in pancreatobiliary cancer? Rev. Invest. Clin. 2001; 53: 51117.